Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2025)

Historic Finished Goods for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $2.8 million.

  • Mirum Pharmaceuticals' Finished Goods fell 3737.35% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 3737.35%. This contributed to the annual value of $3.3 million for FY2024, which is 6521.55% down from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Finished Goods stood at $2.8 million for Q3 2025, which was down 3737.35% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Finished Goods registered a high of $11.3 million during Q3 2023, and its lowest value of $87000.0 during Q4 2021.
  • Over the past 5 years, Mirum Pharmaceuticals' median Finished Goods value was $3.1 million (recorded in 2024), while the average stood at $3.4 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Finished Goods skyrocketed by 620000.0% in 2023, and later tumbled by 6521.55% in 2024.
  • Mirum Pharmaceuticals' Finished Goods (Quarter) stood at $87000.0 in 2021, then skyrocketed by 145.98% to $214000.0 in 2022, then skyrocketed by 4311.68% to $9.4 million in 2023, then plummeted by 65.22% to $3.3 million in 2024, then fell by 13.31% to $2.8 million in 2025.
  • Its Finished Goods was $2.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.6 million in Q1 2025.